secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2026-09-14T11:15:30+00:00
Accession:  0001193125-26-389836
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio names José Trevejo CMO and Ellie Hershberger CDO; bempikibart registration program targeted H1 2027
--------------------------------------------------------------------------------

- José Trevejo, M.D., Ph.D. named CMO; ex-CMO at Tarsus (helped win FDA approval of XDEMVY for Demodex blepharitis) and ex-CDO at Rocket Pharmaceuticals.
- Ellie Hershberger, Pharm.D. named CDO; ex-CDO at Adagio/Invivyd, led antibody from IND-enabling to Phase 3 and helped raise ~$356M in IPO gross proceeds.
- Company targets advancing bempikibart into registration-directed program for severe or very severe alopecia areata in first half of 2027.
- Q32 Bio says SIGNAL-AA Part B showed meaningful hair regrowth, early durability off-drug, and generally well-tolerated safety profile for bempikibart.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/0001193125-26-389836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/d158730d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-389836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer